Skip to content

The EMBER Trial for Weight Management Engagement

The EMBER Trial for Weight Management Engagement

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05424081
Enrollment
470
Registered
2022-06-21
Start date
2022-09-19
Completion date
2025-03-31
Last updated
2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, weight loss, treatment engagement

Brief summary

This study will test whether EMBER, a self-help tool to increase weight loss treatment engagement, helps veterans engage in Veterans Health Administration (VHA) weight management programs. Participants will be randomly assigned to receive EMBER or a list of weight management programs (the control group). They will answer questions about health beliefs and behaviors and share information from their medical record at the start of the study, 2-months after the start of the study, and 6-months after the start of the study. Participants will receive compensation for each of these contacts. Participants will also receive a reminder call 10 days after they enroll in the study. All study contacts will be over the phone. The main hypothesis is that people who receive EMBER will be more likely to use VHA weight management programs than people in the control group.

Detailed description

Background Almost 40% of veterans using the Veterans Health Administration (VHA) have obesity. However, few patients use VHA's effective weight management programs. This study tests the effectiveness of EMBER, a self-directed tool with the goal of Enhancing Motivation for Better Engagement and Reach (EMBER) for weight management. It is available in paper and digital formats. EMBER is not a weight management program, instead it engages veterans in existing programs by informing and guiding choices about weight management. Specific Aims 1. Assess whether veterans randomized to EMBER are more likely to have any weight management engagement at 2-month follow-up (per electronic medical record data supplemented with self-report) compared to those randomized to the control arm (information sheet listing available programs). (Primary Outcome) 2. Assess whether veterans randomized to EMBER have greater weight management program retention, weight management behaviors (e.g., physical activity), weight loss, and quality of life gains at 6-month follow-up compared to those randomized to the control arm. (Secondary Outcomes) 3. Assess factors likely to affect EMBER's implementation. Preliminary implementation outcomes will be assessed via RE-AIM (Reach, Effectiveness, Implementation) and the Proctor et al. implementation outcomes framework (Acceptability, Appropriateness, Costs, Fidelity). (Implementation Outcomes) Methodology Randomized two site Hybrid Type 1 Effectiveness-Implementation Trial among veteran primary care patients with obesity in VA. Participants (N=470) will be randomized to EMBER or a control condition consisting of a list of available weight management programs. Logistic regressions will be used to assess Aims 1 and 2. Aim 3 results are descriptive.

Interventions

BEHAVIORALEMBER

Self-help tool to increase weight management engagement

BEHAVIORALControl

List of weight management programs

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Masking description

Participant outcomes will be assessed by an outside company with no knowledge of randomization status.

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
Yes

Inclusion criteria

* Veteran using primary care at VA Palo Alto or Houston in prior year * BMI greater than or equal to 30 kg/m2

Exclusion criteria

* Age 80 or older * Documentation of a suicide attempt in the past 30 days * Hospitalization in the past 30 days * Documentation or other evidence of cognitive impairment * VA weight management program use in past 2 years * Self-report from potential participant that they will not be in town for the majority of the 2 months following baseline * Self-report from potential participant they plan to leave VA Palo Alto or Houston within the next 6 months * Under age 18

Design outcomes

Primary

MeasureTime frameDescription
Weight Management Use2-months post randomizationDichotomous variable representing whether participant has 1+ VA weight management visits in the 2 months after baseline, per administrative data and/or self-report of use of VA weight management programs via single item question.

Secondary

MeasureTime frameDescription
Weight Management Use6-months post randomizationDichotomous variable representing whether participant has 1+ VA weight management visits in the 6 months after baseline, per administrative data and/or self-report of use of VA weight management programs via single item question.
Number of Weight Management Visits6-months post-randomizationNumber of weight management program visits per administrative data.
New Weight Management Behavior2-months post randomizationCount patients with new weight management behaviors since baseline visit via self-report to question based on NHANES item assessing whether participant tried to lose weight and how. Any change is considered meaningful.
Quality of Life (Veterans RAND 12 Item Health Survey (VR-12))2--months post randomizationSelf-report of quality of life as assessed with the VR12 physical and mental health composite scores (Boston University School of Public Health). Scores are standardized T-scores with mean = 50 and a standard deviation of 10. For individuals on the physical health score, a 6.5 unit change is considering clinically meaningful. For individuals on the mental health score, a 7.9 unit change is considering clinically meaningful. At the population level, a 1 unit change is considered clinically meaningful. Higher scores represent better quality of life.
Weight Loss6-months post randomizationNumber of participants with at least 5% weight loss at 6-months based on difference between self-reported weight at baseline and 6-months, supplemented with medical record data when possible.
Physical Activity (The Stanford Leisure-Time Activity Categorical Item (L-Cat))2-months post randomizationMeasured with Stanford Leisure-Time Activity Categorical Item (L-Cat), which is a 6-level categorical measure with lower scores indicating less physical activity, which we scored from 1-6. An increase of one category is a clinically meaningful difference.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJessica Yelena Breland, PhD MS BA

VA Palo Alto Health Care System, Palo Alto, CA

Participant flow

Recruitment details

Potential participants were identified at the Palo and Houston VA medical centers based on administrative and clinical data. Recruitment occurred between 2022 and 2024.

Pre-assignment details

Four participants were enrolled, but were not randomized because they did not complete the baseline assessment (n=3) or because they were found to be ineligible after enrollment (n=1).

Baseline characteristics

Characteristic
Age, Continuous56.79 years
STANDARD_DEVIATION 14.08
Ethnicity (NIH/OMB)
Hispanic or Latino
29 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
196 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
13 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
13 Participants
Race/Ethnicity, Customized
Another race
8 Participants
Race/Ethnicity, Customized
Asian
14 Participants
Race/Ethnicity, Customized
Black or African American
141 Participants
Race/Ethnicity, Customized
Declined to answer
4 Participants
Race/Ethnicity, Customized
Native Hawaiian or Pacific Islander
3 Participants
Race/Ethnicity, Customized
White
263 Participants
Sex: Female, Male
Female
79 Participants
Sex: Female, Male
Male
151 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 2330 / 2330 / 470
other
Total, other adverse events
0 / 2331 / 2331 / 470
serious
Total, serious adverse events
0 / 2330 / 2330 / 470

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026